Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences

Objective: The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Methods: Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients...

Descripción completa

Detalles Bibliográficos
Autores: Gratacós, Jordi, Pontes, Caridad, Juanola, Xavier, Sanz Sanz, Jesús, Torres, Ferran, Avendaño Solá, Cristina, Vallano, Antoni, Calvo, Gonzalo, Miguel Mendieta, Eugenio de, Sanmartí, Raimon, Almirall, Miriam, Aparicio, Maria, Sellas, Agustí, Vives, Roser, Albiñana, Nestor, Moreno, Mireia, Clavaguera, Teresa, Torre-Alonso, Juan Carlos, Veroz, Raúl, Rodríguez-Lozano, Carlos, Linares, Luís Francisco, Urruticoechea Arana, Ana, Collantes, Eduardo, Morlà, Rosa María, Reina, Dèlia, Cuende, Eduardo, Zarco, Pedro, Fernández-Espartero, Maria Cruz, García de Vicuña Pinedo, María del Rosario, Montilla, Carlos Alberto, Villalba, Alejandro, Pascual, Dora, Campos, Cristina, Juan, Antonio, Ariza, Rafael, Díaz-Miguel, Consuelo, Maqueda, Manuel, Fernández-Dapica, Maria Pilar, Fernández-Prada, Manuel, Batlle, Enrique, González-Fernández, Carlos, Queiro, Rubén
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/688583
Acceso en línea:http://hdl.handle.net/10486/688583
https://dx.doi.org/10.1186/s13075-018-1772-z
Access Level:acceso abierto
Palabra clave:Dose-tapering
Non-inferiority
TNF inhibitors
Spondyloarthritis
Medicina
Descripción
Sumario:Objective: The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis. Methods: Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Patients were randomized by automated central allocation to continue the same TNFi dose schedule, or to reduce the dose by roughly half according to the protocol. The main outcome was the proportion of subjects with LDA after 1 year. Serious adverse reactions or infections were recorded. Results: The trial stopped due to end of the funding period, after 126 patients were randomized; 113 patients (84.1% male, mean age (SD) 45.6 (13.0) years) were included in the main per-protocol subset. Non-inferiority was concluded for LDA at 1 year (47/55 (83.8%) patients in the full-dose and 48/58 (81.3%) patients in the reduced-dose arm, adjusted difference (95% CI) - 2.5% (- 16.6% to 11.7%)). Serious adverse reactions or infections were reported in 7/62 patients (11.3%) assigned to full dose and 2/61 patients (3.3%) assigned to reduced dose (p value = 0.164). Conclusion: In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. Trial registration: EU Clinical Trials Registry, EudraCT 2011-005871-18 and ClinicalTrials.gov, NCT01604629.

Similares en LA Referencia